AR and breast cancer: While normal and non-neoplastic cells were resistant to YJ9069 (IC50 > 10,000 nM), androgen receptor (AR)-positive prostate and breast cancer cells were preferentially sensitive (IC50 < 500 nM) (Figure 1G).